leadf
logo-loader
viewAstraZeneca

AstraZeneca says EU, UK approve cancer drug for additional dosing option

This new dosing option is consistent with the approved Imfinzi dosing in another type of tumour

AstraZeneca - AstraZeneca says EU, UK approve cancer drug for additional dosing option

AstraZeneca PLC (LON:AZN) said Imfinzi has been approved in the EU and the UK for an additional dosing option in locally advanced, unresectable non-small cell lung cancer (NSCLC).

Lung cancer is the leading cause of cancer death and 80%-85% of patients with lung cancer have NSCLC.

READ: AstraZeneca completes sale of heart failure treatment commercial rights for US$400mln

This new dosing option is consistent with the approved Imfinzi dosing in extensive-stage small cell lung cancer and is available to patients with locally advanced, unresectable NSCLC weighing more than 30 kilos.

Eligible patients will be adults whose tumours express a protein called PD-L1 on at least 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy.

The approval follows an accelerated assessment by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, which recommended approval last month. This CHMP recommendation and approval also apply to the UK.

"Less-frequent dosing is important for cancer patients, and may be particularly relevant right now for those suffering from lung cancer, who are especially vulnerable to complications from COVID-19,” said Luis Paz-Ares, chair of the Medical Oncology Department at the Hospital Universitario Doce de Octubre, in Madrid, who was the principal investigator of clinical trials.

“Patients with cancer should be able to focus on living their lives as much as possible and doctors can now offer them a more convenient dosing option that could reduce medical visits by half and help avoid unnecessary risk of exposure to infection in the healthcare setting."

Quick facts: AstraZeneca

Price: 6880 GBX

LSE:AZN
Market: LSE
Market Cap: £90.31 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Spectra Systems sees 3.5x increased demand of banknote authentication orders...

Spectra Systems Corporation (LON:SPSY) CEO Dr. Nabil Lawandy tells Proactive the Rhode Island-based banknote authentication focused group is seeing an increased demand for bank notes globally, partially fueled by the coronavirus pandemic. Lawandy says Spectra Systems' recent orders received...

5 hours, 49 minutes ago

2 min read